David Alan Campbell, President and CEO at Janux Therapeutics, Inc. (JANX), sold 25,000 shares at $56.19 ($1.4M) on 2024-12-24, disclosed to the SEC on 2024-12-27.
Scheduled sale ($1.4M) by President and CEO under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| JANX | SELL | 2024-12-03 | $1.0M | — | Filing → |
| JANX | SELL | 2024-11-27 | $2.6M | — | Filing → |
| JANX | SELL | 2024-10-30 | $2.7M | — | Filing → |